A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
A phase 3 trial of Trastuzumab pamirtecan run by DualityBio Inc. in her2-positive breast cancer, active.
Overview
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer is a phase 3 interventional study registered as NCT06265428 by DualityBio Inc., with 228 participants enrolled, started 2024-01-29. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase III, Multicenter, Open-label, Randomized Study to Compare DB-1303 Versus T-DM1 in Patients With HER2-positive Unresectable/Metastatic Breast Cancer Who Have Been Treated With Trastuzumab and a Taxane (Dynasty-Breast01)
Phase
Phase 3
Sponsor
DualityBio Inc.
Registry
Enrolled
228